congresses-banner
The content contained is subject
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
Disease Area Tab
PublicationView
Poster
Pexidartinib
CTOS 2024 | November 13- 16, 2024
A long-term phase 4 study to evaluate the risk of idiosyncratic hepatotoxicity associated with pexidartinib treatment
Poster
I-DXd
SITC 2024 | November 6-10, 2024
Evaluation of immunomodulatory effects of ifinatamab deruxtecan (I-DXd) in the IDeate-PanTumor01 phase 1/2 study in patients with advanced solid tumors
Poster
Pexidartinib
CTOS 2024 | November 13- 16, 2024
Health-related quality of life from a phase 4 global clinical study to evaluate discontinuation and rechallenge of pexidartinib in patients with tenosynovial giant cell tumor (TGCT) previously treated with pexidartinib
Poster
HER3-DXd
ASCO 2024 | May 31 - June 4, 2024
HERTHENA-PanTumor01: A global, multicohort, phase 2 trial of HER3-DXd in relapsed/refractory metastatic solid tumors
Poster
HER3-DXd
ESMO 2024 | September 13-17, 2024
HERTHENA-PanTumor01: A global, phase 2 trial of HER3-DXd in metastatic solid tumors
Poster
Pexidartinib
CTOS 2024 | November 13- 16, 2024
Pexidartinib upfront in a case study of tenosynovial giant cell tumor: Proof of concept for a treatment paradigm shift
Oral
Pexidartinib
CTOS 2024 | November 13- 16, 2024
Pexidartinib use in patients with tenosynovial giant cell tumor: An analysis of the phase III randomized ENLIVEN clinical trial according to surgical history
Poster
R-DXd
ACoP15 | November 10-13, 2024
Pharmacokinetic-pharmacodynamic analysis of myelosuppression with raludotatug deruxtecan (R-DXd) in patients with advanced solid tumors
Poster
Valemetostat
ACoP15 | November 10-13, 2024
Population pharmacokinetic and exposure-response modelling analyses to support valemetostat dose recommendations in relapsed/refractory (R/R) peripheral T-cell lymphoma (PTCL) patients
Poster
Pexidartinib
CTOS 2024 | November 13- 16, 2024
Real-world experience of patients newly initiated on pexidartinib for tenosynovial giant cell tumor (TGCT)
Pages:
1 2